Malard Florent, Milpied Noel, Blaise Didier, Chevallier Patrice, Michallet Mauricette, Lioure Bruno, Clément Laurence, Hicheri Yosr, Cordonnier Catherine, Huynh Anne, Yakoub-Agha Ibrahim, Peffault de Latour Regis, Mohty Mohamad
Hematology Department, Nantes Hospital and University Center (CHU), Nantes, France; INSERM UMR 938 and Pierre et Marie Curie University, Paris, France.
Hematology and Cell Therapy Department, University Hospital and University of Bordeaux, Bordeaux, France.
Biol Blood Marrow Transplant. 2015 Jun;21(6):1059-67. doi: 10.1016/j.bbmt.2015.02.014. Epub 2015 Feb 20.
This retrospective report compared the 4-year outcomes of allogeneic stem cell transplantation (allo-SCT) in 651 adult patients with acute myeloid leukemia receiving a reduced-intensity (RIC) or nonmyeloablative conditioning (NMA) regimen according to the type of unrelated donors. These were either umbilical cord blood (UCB, n = 205), a 9/10 mismatched unrelated donor (MisMUD, n = 99), or a 10/10 matched unrelated donor (MUD, n = 347) graft. Neutrophil recovery was slower in UCB (74.5% by day 42) compared with MisMUD (94.8%) and MUD (95.6%) (P < .001). There was no significant difference in nonrelapse mortality between UCB and both MUD (hazard ratio [HR], 1.05; 95% confidence interval [CI], .62 to 1.78; P = .85) and MisMUD (HR, 1.58; 95% CI, .88 to 2.83; P = .13) The relapse/progression was similar between UCB and MisMUD (HR, .62; 95% CI, .37 to 1.03; P = .07), but was significantly lower in MUD compared with UCB (HR, .60; 95% CI, .39 to .92; P = .02). The rate of extensive chronic graft-versus-host disease (GVHD) was similar between UCB and both MUD (HR, 2.15; 95% CI, .93 to 4.97; P = .08) and MisMUD (HR, 1.84; 95% CI, .68 to 4.95; P = .23). The rate of severe grade III and IV acute GVHD was significantly increased in MisMUD compared with UCB (HR, 2.61; 95% CI, 1.30 to 5.23; P = .007). There was no significant difference in overall survival between UCB and both MisMUD (HR, .98; 95% CI, .66 to 1.45; P = .92) and MUD (HR, .74; 95% CI, .52 to 1.03; P = .08). These data suggest that in the setting of RIC/NMA, allo-SCT UCB is a valid alternative graft source, with significantly less chronic GVHD, compared with MisMUD, when there is no MUD available or when urgent transplantation is needed.
本回顾性报告比较了651例接受降低强度(RIC)或非清髓性预处理(NMA)方案的成年急性髓系白血病患者,根据无关供者类型进行异基因干细胞移植(allo-SCT)的4年结局。这些供者类型分别为脐带血(UCB,n = 205)、9/10错配无关供者(MisMUD,n = 99)或10/10匹配无关供者(MUD,n = 347)的移植物。与MisMUD(94.8%)和MUD(95.6%)相比,UCB组中性粒细胞恢复较慢(第42天时为74.5%)(P <.001)。UCB与MUD(风险比[HR],1.05;95%置信区间[CI],.62至1.78;P =.85)和MisMUD(HR,1.58;95% CI,.88至2.83;P =.13)的非复发死亡率无显著差异。UCB与MisMUD的复发/进展情况相似(HR,.62;95% CI,.37至1.03;P =.07),但MUD与UCB相比复发率显著更低(HR,.60;95% CI,.39至.92;P =.02)。UCB与MUD(HR,2.15;95% CI,.93至4.97;P =.08)和MisMUD(HR,1.84;95% CI,.68至4.95;P =.23)的广泛慢性移植物抗宿主病(GVHD)发生率相似。与UCB相比,MisMUD的重度III级和IV级急性GVHD发生率显著增加(HR,2.61;95% CI,1.30至5.23;P =.007)。UCB与MisMUD(HR,.98;95% CI,.66至1.45;P =.92)和MUD(HR,.74;95% CI,.52至1.03;P =.08)的总生存率无显著差异。这些数据表明,在RIC/NMA情况下,当没有MUD可用或需要紧急移植时,allo-SCT UCB是一种有效的替代移植物来源,与MisMUD相比,慢性GVHD显著更少。